Literature DB >> 22825552

[Mesenchymal stem cells and rheumatism. State of the art].

J Voswinkel1, A Chapel.   

Abstract

Mesenchymal stem cells (MSC) are multipotent. They are able to regenerate tissue damage and, in parallel, inhibit inflammation and fibrosis. As they are non-immunogenic, MSCs can be safely transplanted using autologous and allogeneic procedures: an option for refractory connective tissue diseases and osteoarthritis.

Entities:  

Mesh：

Year:  2012        PMID： 22825552     DOI： 10.1007/s00393-011-0950-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  17 in total

1.  [Mesenchymal stem cells: A therapeutic update].

Authors:  Christian Jorgensen; Frédéric Deschaseaux; Valérie Planat-Benard; Eric Gabison
Journal:  Med Sci (Paris)       Date:  2011-03-30       Impact factor: 0.818

2.  Principles of cartilage repair and regeneration.

Authors:  A I Caplan; M Elyaderani; Y Mochizuki; S Wakitani; V M Goldberg
Journal:  Clin Orthop Relat Res       Date:  1997-09       Impact factor: 4.176

3.  Spontaneous human adult stem cell transformation.

Authors:  Daniel Rubio; Javier Garcia-Castro; María C Martín; Ricardo de la Fuente; Juan C Cigudosa; Alison C Lloyd; Antonio Bernad
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

4.  Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study.

Authors:  Jun Liang; Huayong Zhang; Bingzhu Hua; Hong Wang; Liwei Lu; Songtao Shi; Yayi Hou; Xiaofeng Zeng; Gary S Gilkeson; Lingyun Sun
Journal:  Ann Rheum Dis       Date:  2010-08       Impact factor: 19.103

5.  Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons.

Authors:  Kirstin J Beggs; Alex Lyubimov; Jade N Borneman; Amelia Bartholomew; Annemarie Moseley; Robert Dodds; Michael P Archambault; Alan K Smith; Kevin R McIntosh
Journal:  Cell Transplant       Date:  2006       Impact factor: 4.064

6.  Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice.

Authors:  Karoliina Pelttari; Anja Winter; Eric Steck; Katrin Goetzke; Thea Hennig; Bjoern Gunnar Ochs; Thomas Aigner; Wiltrud Richter
Journal:  Arthritis Rheum       Date:  2006-10

7.  Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.

Authors:  Maria Ester Bernardo; Nadia Zaffaroni; Francesca Novara; Angela Maria Cometa; Maria Antonietta Avanzini; Antonia Moretta; Daniela Montagna; Rita Maccario; Raffaella Villa; Maria Grazia Daidone; Orsetta Zuffardi; Franco Locatelli
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis.

Authors:  J Larghero; D Farge; A Braccini; S Lecourt; A Scherberich; E Foïs; F Verrecchia; T Daikeler; E Gluckman; A Tyndall; C Bocelli-Tyndall
Journal:  Ann Rheum Dis       Date:  2007-05-25       Impact factor: 19.103

9.  Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells.

Authors:  Aisha Nasef; Alain Chapel; Christelle Mazurier; Sandrine Bouchet; Manuel Lopez; Noelle Mathieu; Luc Sensebé; Yizhuo Zhang; Norbert-Claude Gorin; Dominique Thierry; Loïc Fouillard
Journal:  Gene Expr       Date:  2007

10.  Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation.

Authors:  Karin Tarte; Julien Gaillard; Jean-Jacques Lataillade; Loic Fouillard; Martine Becker; Hossein Mossafa; Andrei Tchirkov; Hélène Rouard; Catherine Henry; Marie Splingard; Joelle Dulong; Delphine Monnier; Patrick Gourmelon; Norbert-Claude Gorin; Luc Sensebé
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113
View more
  6 in total

1.  New insights for pelvic radiation disease treatment: Multipotent stromal cell is a promise mainstay treatment for the restoration of abdominopelvic severe chronic damages induced by radiotherapy.

Authors:  Alain Chapel; Sabine Francois; Luc Douay; Marc Benderitter; Jan Voswinkel
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 2.  Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review.

Authors:  Jan Voswinkel; Sabine Francois; Jean-Marc Simon; Marc Benderitter; Norbert-Claude Gorin; Mohamad Mohty; Loïc Fouillard; Alain Chapel
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

3.  Fifteen years of preclinical and clinical experiences about biotherapy treatment of lesions induced by accidental irradiation and radiotherapy.

Authors:  Alain Chapel; Sabine Francois; Luc Douay; Marc Benderitter; Jan Voswinkel
Journal:  World J Stem Cells       Date:  2013-07-26       Impact factor: 5.326

Review 4.  Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.

Authors:  Jan Voswinkel; Sabine Francois; Norbert-Claude Gorin; Alain Chapel
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

5.  Mesenchymal Stem Cells in Combination with Hyaluronic Acid for Articular Cartilage Defects.

Authors:  Lang Li; Xin Duan; Zhaoxin Fan; Long Chen; Fei Xing; Zhao Xu; Qiang Chen; Zhou Xiang
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

6.  Advantage of fat-derived CD73 positive cells from multiple human tissues, prospective isolated mesenchymal stromal cells.

Authors:  Eriko G Suto; Yo Mabuchi; Saki Toyota; Miyu Taguchi; Yuna Naraoka; Natsumi Itakura; Yoh Matsuoka; Yasuhisa Fujii; Naoyuki Miyasaka; Chihiro Akazawa
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.